Biocon Ltd Sector Top 20
Biopharmaceutical company developing affordable medicines across generics, biosimilars, research services, and novel biologics.
Valuation
Returns
Per share
Growth · year on year
Ownership
Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.
How this score is calculated
| Measure | Value | Scores | Source |
|---|---|---|---|
| P/E What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall. Computed on a different basis this reads 657.46, which would score 0/100. Scored on the figure shown. |
141.55 | 0/100 | BSE |
| P/B Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons. |
2.35 | 75/100 | Market data |
| ROE Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business. |
0.19 | 0/100 | Market data |
| ROCE Return on capital employed — the same idea including debt, so it is harder to flatter with leverage. |
0.91 | 0/100 | Market data |
| Profit growth Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do. |
-93.89 | 0/100 | Market data |
| Sales growth Year-on-year growth in revenue. |
4.63 | 25/100 | Market data |
| Promoter holding How much of the company its founders and controlling group still own. Higher usually means their money moves with yours. |
44.68 | 75/100 | Market data |
The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.
Biocon Ltd: Funding Rounds
| Date | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 31 Mar 2004 | IPO | ₹315 Cr | source |
News on Biocon Ltd
-
25 Sep 2026
Biocon Malaysia Insulin Line Clears MHRA -
22 Sep 2026
Biocon Pebrilzo Clears EMA Scientific Gate
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free ValidationFAQs on Biocon Ltd
Who founded Biocon Ltd?
Biocon Ltd was founded by Kiran Mazumdar-Shaw in 1978.
How much funding has Biocon Ltd raised?
Biocon Ltd has raised $68.55 Mn across 1 tracked funding round(s), most recently on 2004-03-31. Figures are compiled from cited public sources.
What does Biocon Ltd do?
Biopharmaceutical company developing affordable medicines across generics, biosimilars, research services, and novel biologics.